SK Biopharmaceuticals to Present Key Cenobamate Data at American Academy of Neurology Meeting
SK Biopharmaceuticals’ US subsidiary, SK Life Science, announced that it will present multiple posters at the 2026 American Academy of Neurology (AAN) Annual Meeting, which will be held in Chicago, Illinois, from April 18 to April 22.
SK Life Science will present clinical results, real-world evidence (RWE), pharmacokinetic data, and long-term efficacy data for cenobamate—an innovative anti-epileptic drug (marketed in the US as XCOPRI®)—during the event. Additionally, the company will share an in-depth analysis of real treatment experiences and communication barriers faced by people with epilepsy and healthcare professionals.
In particular, the company will unveil new methodological analysis results from the survey “Hope, Hesitation, and Hard Truths,” which deeply explores communication gaps between people with epilepsy and healthcare professionals. This survey was designed to examine perception differences between people with epilepsy and healthcare professionals, and was first released in November of last year during “Epilepsy Awareness Month.” The upcoming presentation will feature detailed analyses of the survey design and respondent groups, as well as additional insights reflecting the perspectives of various stakeholders.
Sunita Misra, Chief Medical Officer of SK Life Science, explained, “Understanding the communication gap between patients and healthcare professionals is crucial to improving the quality of epilepsy care.”
She added, “The ‘Hope, Hesitation, and Hard Truths’ survey provides valuable insights into the experiences of various stakeholders involved in epilepsy care, including patients, neurologists and epileptologists, and advanced practice providers (APPs). By considering these diverse perspectives, we can better understand the barriers within the clinical process and identify communication gaps that may influence patient management and decision-making.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, SK Life Science will present a total of 10 posters at this meeting, covering the clinical outcomes, real-world evidence (RWE), and pharmacokinetic characteristics of cenobamate. All abstracts presented at the American Academy of Neurology meeting can be found on the official AAN website.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.